The short answer: four main reasons candidacy is ruled out

ChondroFiller hip injection works because the collagen scaffold draws the patient's own progenitor cells into the damaged area of the hip joint, where they can produce repair tissue. When something prevents that biology from functioning — or when the hip has moved past the point where cartilage preservation is the right goal — the injection is not the appropriate next step.

Four broad categories account for most cases of non-candidacy: an active infection inside the hip joint, hip disease that has progressed to the stage where total hip replacement is the better option, an untreated mechanical problem such as major joint instability or malalignment, and a known allergy to animal-derived collagen (ChondroFiller is murine-derived). A fifth consideration is routing rather than exclusion — patients with a single, isolated focal cartilage defect may be better served by a different delivery method for the same product, not by the injection pathway.

These categories are a practical guide, not a self-assessment checklist. Confirming whether any of them apply requires individual clinical evaluation, including imaging of the hip.

Active infection in the hip joint

Septic arthritis — active bacterial infection inside the hip joint — is the clearest and most non-negotiable item on the exclusion list. Placing any intra-articular biological scaffold, including ChondroFiller, into an infected hip risks worsening or spreading the infection and completely disrupts the cell-recruitment process the scaffold depends on. An inflamed, bacterially hostile environment cannot support progenitor cell migration; the material would be unable to function as intended even if it were safe to inject.

This is not a relative or case-by-case decision. Infection must be fully cleared and confirmed absent before any cartilage regeneration pathway — whether injection or otherwise — is considered for the hip. Once the joint is confirmed infection-free, ChondroFiller candidacy can be assessed on its own clinical merits.

Hip disease that has reached the point of needing replacement

Cartilage loss severe enough to warrant total hip replacement represents a genuine boundary for ChondroFiller injection. The scaffold functions by recruiting progenitor cells from perilesional tissue — the viable cartilage and synovium surrounding the damaged area. Where cartilage is entirely absent across the hip joint and the surrounding tissue can no longer contribute those cells, the biological substrate the scaffold depends on is gone. In that situation, joint replacement addresses the problem in a way that a regenerative injection cannot.

The difficulty is that radiological severity alone does not draw this line reliably. A scan reporting 'bone on bone' or Kellgren-Lawrence Grade IV osteoarthritis is a description of X-ray appearance, not a clinical verdict on what treatment is appropriate. Advanced but not fully exhausted hip joints — including those with KL Grade IV changes — remain a target indication for the injection pathway, precisely because the procedure coats the whole joint surface rather than requiring a discrete area of healthy surrounding cartilage. Age, likewise, is not an exclusion criterion; there is no upper limit.

The real boundary sits between a hip that is severely worn but biologically workable and one where symptoms, function, and the full clinical picture together point to replacement as the right next step. That distinction cannot be read off a plain radiograph. It requires MRI to assess remaining tissue viability alongside a careful review of symptom progression and individual treatment goals — a clinical judgement, not a scanning threshold.

Untreated instability or significant malalignment in the hip

Abnormal mechanics in the hip joint present a different kind of obstacle — conditional rather than permanent. Where significant instability or malalignment has not been addressed, ChondroFiller injection is not appropriate. The reason is straightforward: if the structural forces acting on the hip remain wrong, they will continue to break down any repair tissue the scaffold produces, making the treatment unlikely to hold.

Femoroacetabular impingement (FAI) is one example of an underlying mechanical problem that, left uncorrected, creates abnormal contact stress across the joint. The principle extends to other forms of malalignment where load distribution within the hip is materially disrupted.

Critically, this exclusion is a 'not yet' rather than a 'never'. Once the mechanical problem has been identified and corrected, the injection pathway may become viable — the required sequence is simply to restore normal hip mechanics first. What counts as 'significant' is determined through clinical assessment, including imaging, rather than by any fixed radiological threshold.

Isolated focal cartilage defects — a routing distinction, not a disqualification

Patients with a single, clearly defined focal cartilage defect — the classic contained lesion with healthy surrounding borders — fall outside the injection pathway for a specific clinical reason, not because ChondroFiller is the wrong treatment.

The injection form is designed for diffuse, multi-surface hip cartilage wear: it coats the joint broadly, providing additive mechanical support across advanced generalised changes, including Kellgren-Lawrence Grade III/IV osteoarthritis. A contained focal defect calls for a different delivery method. Arthroscopic ChondroFiller placement deposits the same scaffold material directly into the base of a discrete lesion, where it rebuilds from the bottom up within healthy cartilage borders — a precision the injection route cannot replicate across a focal site.

For these patients, therefore, the injection pathway is not the appropriate route. The scaffold material is not in question; the mismatch is between defect pattern and delivery method. Isolated Grade III/IV focal lesions with intact surrounding borders, up to 6 cm², are the primary target for the arthroscopic route, where the surgeon can place the scaffold with structural accuracy.

Which route is indicated is determined by MRI and clinical assessment findings — not patient preference alone. Being directed away from the injection pathway in this situation is a routing decision, not a disqualification from ChondroFiller treatment altogether.

Collagen allergy, immunosuppression, and mismatched treatment goals

Three further non-candidacy factors relate not to the hip's anatomy but to the patient's biology and treatment expectations.

ChondroFiller is derived from murine (mouse) Type I collagen. Patients with a known allergy or hypersensitivity to animal-derived or murine collagen products cannot receive it — this is an absolute contraindication, independent of how advanced the hip disease is or how otherwise suitable the patient might appear. Disclosing any history of collagen or animal-protein sensitivity is therefore a routine part of the pre-procedure assessment.

The scaffold's effectiveness also depends on the patient's own progenitor cells migrating into the collagen matrix and populating it with repair tissue. Severe immunosuppression — whether from medication or underlying disease — may limit that cell recruitment and reduce the treatment's ability to support repair. This is a conditional rather than absolute exclusion, assessed individually during clinical review.

Separate from biology, there is the question of expectation. Many patients arrive having previously received corticosteroid injections, which typically act within days. ChondroFiller works through a biological repair process that unfolds over three to six months. Patients whose primary goal is rapid symptom relief are not well matched to this timeline and are better guided towards a discussion of alternatives.

Together, these three factors — allergy profile, immune status, and treatment expectations — form a cluster that is distinct from the anatomical exclusions covered in earlier sections. Identifying them at assessment, rather than after treatment, is why the clinical process at Lincolnshire Hip covers allergies, current medications, and personal goals before any procedure is recommended. Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.